This weekend, New York City cardiologist Dr. Nieca Goldberg and her nurse spent their Saturday fielding phone calls from patients. The issue was a recent study of the cholesterol drug Vytorin.
Dr. Goldberg says she enjoys educating patients about their health, but has been frustrated lately by how much time she has spent trying to undo confusion about the latest cholesterol drug study. The report showed that Vytorin, an expensive branded drug, did not do any better job of protecting arteries than a cheaper generic drug. It did not do any worse either, but the findings. This surprised the scientific community, have alarmed many patients. Dr. Goldberg says one of her patients thought the drug was being pulled off the market, and others thought the study showed the drug might be risky. Neither is true.